BioMarin Announces Acceptance of Late Breaking Abstract for BMN 270 at the World Federation of Hemophilia (WFH) 2016 World Congress July 27 in Orlando, FL
June 20, 2016 16:35 ET
|
BioMarin Pharmaceutical Inc.
SAN RAFAEL, Calif., June 20, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced the upcoming oral presentation summarizing a late breaking abstract accepted for...
BioMarin Announces Withdrawal of Market Authorization Application for Kyndrisa™ (drisapersen) in Europe
May 31, 2016 16:05 ET
|
BioMarin Pharmaceutical Inc.
SAN RAFAEL, Calif., May 31, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that it has withdrawn its Kyndrisa™ (drisapersen) Marketing Authorization...
BioMarin to Attend Upcoming Investor Conferences
May 04, 2016 08:30 ET
|
BioMarin Pharmaceutical Inc.
- Bank of America Merrill Lynch 2016 Health Care Conference on May 11 in Las Vegas - Goldman Sachs 37th Annual Global Healthcare Conference on June 9 in Ranchos Palos Verdes,...
BioMarin Announces EMA Grants Accelerated Assessment for Cerliponase Alfa, Experimental Treatment for a Form of Batten Disease
May 03, 2016 08:25 ET
|
BioMarin Pharmaceutical Inc.
EU and U.S. Marketing Application Submissions Planned for Mid-Year 2016 Company Seeking Priority Review in the U.S. SAN RAFAEL, Calif., May 03, 2016 (GLOBE NEWSWIRE) -- BioMarin...
BioMarin Announces First Quarter 2016 Financial Results
April 28, 2016 16:01 ET
|
BioMarin Pharmaceutical Inc.
-First Quarter 2016 Total BioMarin Revenue Increases 16.7% Y/Y to $236.7 million -Vimizim Net Product Revenue Increases 43.5% Y/Y and Contributes $72.6 million in the First Quarter 2016; Vimizim...
BioMarin Enrolls First Patient in Phase 1/2 Trial of NAGLU Fusion Protein BMN 250 for Treatment of MPS IIIB (Sanfilippo B Syndrome)
April 21, 2016 16:30 ET
|
BioMarin Pharmaceutical Inc.
SAN RAFAEL, Calif., April 21, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that it has enrolled the first patient in a Phase 1/2 trial for BMN 250, an...
BioMarin Provides Program Update on Vosoritide in Achondroplasia
April 20, 2016 10:36 ET
|
BioMarin Pharmaceutical Inc.
New Data Shows Durable and Consistent Effects on Mean Annualized Growth Velocityfor up to 12 months with Increases of 46%-65% from Baseline Phase 3 Randomized Controlled Study Planned to Start at...
BioMarin Provides Encouraging Preliminary Data on First 8 Patients in Hemophilia A Gene Therapy Program
April 20, 2016 08:30 ET
|
BioMarin Pharmaceutical Inc.
Two High Dose Patients Show Increasing Levels of Factor VIII Above 50% Five of Six High Dose Patients Show Factor VIII Levels Above 5% SAN RAFAEL, Calif., April 20, 2016 (GLOBE NEWSWIRE) -- ...
BioMarin to Highlight Breadth of Innovative Development Pipeline at R&D Day on April 20th in New York
April 18, 2016 08:30 ET
|
BioMarin Pharmaceutical Inc.
SAN RAFAEL, Calif., April 18, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) will host an R&D Day from 8am (ET) to 12pm (ET) on Wednesday, April 20, 2016 in New York City....
BioMarin to Host First Quarter 2016 Financial Results Conference Call and Webcast on Thursday, April 28 at 4:30pm ET
April 12, 2016 08:30 ET
|
BioMarin Pharmaceutical Inc.
SAN RAFAEL, Calif., April 12, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will...